willow health glp 1 Start (@startwillow) • Instagram photos and videos Willow Health, Body-Dysmorphia, and the

SGLT2 inhibition: a new era in renoprotective medicine

The platform addresses a massive market opportunity at the intersection of the $28.65B global weight loss supplement market and the $39.74B global probiotic drink market, with initial focus on the U.S

The discovery would eventually launch a new class of diabetes drugs known as GLP-1 receptor agonists, the first of which was approved in 2005

Originally developed for type 2 diabetes, GLP-1 receptor agonists, like semaglutide, work by stimulating insulin release, slowing digestion, and signaling fullness in the brain

Patients should be advised of the potential for experiencing GI adverse effects after switching to a different GLP-1 receptor agonist and that (as with the initiation of the prior GLP-1 receptor agonist) they should expect these effects to improve over time